Do not exceed recommended dose Not Suitable For: - Children under 30 age - Breast feeder
Krishnan A, Sims OT, Surapaneni PK, Woreta TA, Alqahtani SA (2023) Risk of adverse cardiovascular outcomes among persons living with HIV and nonalcoholic fatty liver disease: a multicenter matched cohort study
Antihyperalgesic effects of (R,E)-N-(2-hydroxy-2,3-dihydro-1H-inden-4-yl)-3-(2-(piperidin-1-yl)-4-(trifluoromethyl)phenyl)-acrylamide (AMG8562), a novel transient receptor potential vanilloid type 1 modulator that does not cause hyperthermia in rats
Rather than activating only GLP-1 receptors, it is a dual agonist that also targets GIP (glucose-dependent insulinotropic polypeptide) receptors
Reduced tolerance, nausea after fewer drinks, and a general decrease in the desire to drink are commonly reported